Establishment of the 2nd WHO IS for anti-SARS-CoV-2
Report Download the ReportEnquiries Connect with our team of dedicated scientists
The merger of Cerba Research and Viroclinics-DDL
After the acquisition of Viroclinics-DDL by the group Cerba Healthcare, we are delighted to announce that Cerba Research, the group’s global clinical trial central and speciality laboratory services division, has now merged with Viroclinics-DDL, a fast-growing global specialist virology and immunology contract research organisation (CRO).
Cerba Healthcare enters agreement to acquire Viroclinics-DDL expanding and transforming its offering in clinical trials
Cerba HealthCare, a leading global player in medical diagnosis, today announced it has reached agreement to acquire Viroclinics-DDL, a fast-growing global virology and immunology contract research organization (CRO), from Summit Partners.
Viroclinics-DDL and CEPI strengthen partnership with the production of Omicron SARS-CoV-2 variant for distribution in the CEPI COVID-19 Vaccine Testing Network
Today, Viroclinics-DDL, a global Contract Research Organization supporting clinical and preclinical studies for drug and vaccine development and CEPI, the Coalition for Epidemic Preparedness Innovations, signed an agreement which allows Viroclinics-DDL to produce and distribute laboratory stocks of the Omicron SARS-CoV-2 variant for use in CEPI’s centralised COVID-19 vaccine testing network. The produced Omicron SARS-COV-2 variant will be used for the performance of laboratory assays, assessing the neutralizing potential of COVID-19 vaccines against the new variant.
Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus
Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its oral PARP inhibitor, stenoparib, against Coronavirus variant B.1.617.2 (delta variant).
Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2
Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies,
today announced new results on the efficacy of Atriva’s lead candidate zapnometinib against coronaviruses.
Launching our new business unit Viroclinics Xellerate
Viroclinics-DDL, today announced the launch of Viroclinics Xellerate, a newly formed Business Unit focused on clinical trial support and global logistics services.
Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus
Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive results from the further pre-clinical testing of the antiviral activity of its PARP inhibitor, stenoparib, against Coronavirus variant B.1.1.7 (British variant). The Pathogen and Microbiome Institute at Northern Arizona University (NAU), a leading U.S. infectious disease research center, conducted the tests.
Assessment of genetic changes and neurovirulence of shed Sabin and novel type 2 oral polio vaccine viruses
Sabin-strain oral polio vaccines (OPV) can, in rare instances, cause disease in recipients and susceptible contacts or evolve to
become circulating vaccine-derived strains with the potential to cause outbreaks.
Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants
Article Open the article hereEnquiries Connect with our team of dedicated scientists
REPROCELL and VIROCLINICS-DDL Renew Collaboration Agreement in Clinical Research
Rotterdam, the Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a renewal for collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2
Peer Reviewed /PUBMED articleArticle Open the article hereEnquiries Connect with our team of dedicated scientists
Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
Peer Reviewed /PUBMED articleArticle Open the article hereEnquiries Connect with our team of dedicated scientists
ENPICOM and Viroclinics-DDL receive joint MIT R&D ZH subsidy subsidy to accelerate and improve antibody and vaccine discovery and development
Partnership combines Viroclinics-DDL’s diagnostic and high-throughput sequencing experience with ENPICOM’s expertise in bioinformatics and immunomics.
Susceptibility of rabbits to SARS-CoV-2
Peer Reviewed /PUBMED articleArticle Open the article hereEnquiries Connect with our team of dedicated scientists
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
Peer Reviewed /PUBMED articleArticle Open the article hereEnquiries Connect with our team of dedicated scientists
AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets
Peer Reviewed /PUBMED articleArticle Open the article hereEnquiries Connect with our team of dedicated scientists
CEPI establishes global network of laboratories to centralise assessment of COVID-19 vaccine candidates
The Coalition for Epidemic Preparedness Innovations (CEPI) has today announced partnerships with five clinical sample testing laboratories to create a centralised global network to reliably assess and compare the immunological responses generated by COVID-19 vaccine candidates.
Viroclinics-DDL and Infinity BiologiX deepen their partnership
The two companies bring their existing partnership to the next level by developing customized services to assist pharma, biotech and governmental clients with clinical diagnostics and global logistical services.
Immunogenicity and efficacy comparison of MDCK cell-based and egg-based live attenuated influenza vaccines of H5 and H7 subtypes in ferrets
Peer Reviewed / PUBMED article Article Open the article here Enquiries Connect with our team of dedicated scientists
Highly potent anti-SARS-CoV-2 multi-DARP in therapeutic candidates
Peer Reviewed / PUBMED article Article Open the article here Enquiries Connect with our team of dedicated scientists
Thousands of women donate breast milk for Corona research
Since Tuesday evening, some 5,000 women have responded to Emma Children Hospital’s call to donate breast milk. “Our researchers are very enthusiastic about the overwhelming response,” according to a spokesperson of the Emma Children’s hospital, (A unit of Amsterdam UMC University Hospital).
REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research
Rotterdam, The Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a new collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership
Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership to offer integrated, complementary services to advance infectious disease research and COVID-19 therapeutic development.
Davide Molho, DVM joins Viroclinics Biosciences as Chief Executive Officer
Viroclinics Biosciences B.V. (“Viroclinics”) today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company’s new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the company’s CEO since 2011. This transition is part of a planned succession strategy. Dr. Molho’s appointment will take effect on 1 August 2020.
International partnership progresses UQ COVID-19 vaccine project
9 April 2020 The University of Queensland’s potential COVID-19 vaccine is entering an important new phase of testing with the live coronavirus to determine how effectively it induces protection against coronavirus infection. The UQ team will partner with the Dutch...
Viroclinics-DDL Diagnostic Laboratory Team to Support COVID-19 New Drug Investigations
Preceding weeks have made clear that COVID-19 continues to spread and is paralyzing the world. Times are unprecedented and show us how vulnerable we are and how we depend on each other. As a service organization – highly specialized in virology – we will commit ourselves to realign our resources, equipment and materials to new initiatives to test anti-virals, immune modulators and vaccines in the battle against COVID-19.
Summit Partners Announces Growth Equity Investment in Viroclinics
Global growth equity investor Summit Partners today announced a majority investment in Viroclinics Biosciences B.V., a leading specialized contract research organization (CRO) serving the global biopharmaceutical industry. The funding will be used to fuel continued expansion of Viroclinics’ services, capacity and international presence.
Viroclinics Biosciences and DDL Diagnostic Laboratory Join Forces
Viroclinics Biosciences, a leading virology contract research organization, announced today that it has acquired DDL Diagnostic Laboratory, a leading diagnostic solutions provider. The transaction enhances the combined group’s leading global position in anti-viral and vaccine testing and will serve to accelerate their ambitious growth strategy.
Viroclinics Xplore Joins Trade Mission Life Sciences India
October 13th - October 19th, Delhi & Bangalore Viroclinics Xplore continues its cooperation with The Netherlands Enterprise Agency (RVO). Viroclinics experts will join the upcoming trade mission to India from October 13th to October 19th. The health program of the...
